Dr. Jon Inglefield received his Ph.D. from University of Rochester School of Medicine and Dentistry and, in 1997, completed a postdoctoral fellowship at Duke University Medical Center. He subsequently performed cellular toxicology at the Environmental Protection Agency, in vitro immunology and toxicology at 3M Co.’s Pharmaceuticals Division, assay development at Meso Scale Diagnostics, and vaccine clinical development for Emergent BioSolutions. Since 2018, he has led an immunological analysis group at Frederick National Laboratory. Inglefield developed or led development on immunoassay methods for analyzing samples from small-molecule, large-molecule, cell therapy, and vaccine studies using various assay, imaging, and flow cytometry techniques. His group focused on cytokine biology of small-molecule immune stimulants, virus neutralization, and assays on anthrax vaccine correlates of protection. One of their major efforts was analyzing adjuvants for vaccines and managing the accompanying data.
